Stage IIIB Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01134614Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT01708941Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT03033576Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaTreatment
NCT02519322Neoadjuvant and Adjuvant Checkpoint BlockadeTreatment